What Does the Future Hold for Biosimilars in the United States?

Marc O'Connor, Chief Operating Officer of Curant Health, discusses the potential impact of biosimilars on the specialty drug market.

Related Content:

InterviewsBiosimilarsSpecialty Pharmacy

Sativex Does Not Meet Primary Endpoint on Measures of Spasticity for Multiple Sclerosis

Experts: The Hematology-Oncology Pharmacist Great Migration Is Caused by Issues Outside of Burnout That Could Be Quickly Addressed

How to Bring Greater Workforce Diversity to Oncology Pharmacy